Esperion Therapeutics Inc.
NEWS
Esperion announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open..
Esperion announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd.
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
Esperion announced the completion of patient enrollment in the CLEAR Cardiovascular Outcomes Trial.
Esperion announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units to eighteen new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.
Esperion provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019.
Esperion announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology Conference in New York, NY on Monday, August 12, 2019 at 11:00 a.m. Eastern Time.
JOBS
IN THE PRESS